Canada Pension Plan Investment Board’s Amylyx Pharmaceuticals AMLX Stock Holding History

Canada Pension Plan Investment Board’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$496K	Buy	+27,600	New	+$427K	﹤0.01%	1267

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Canada Pension Plan Investment Board's AMLX Position: Q2 2026 in Review

Canada Pension Plan Investment Board opened a new position in Amylyx Pharmaceuticals (AMLX) in Q2 2026: 27,600 shares worth $496K. The stake represents ﹤0.01% of the portfolio and ranks #1267 among its holdings.

206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

Canada Pension Plan Investment Board held 27,600 shares of Amylyx Pharmaceuticals worth $496K as of Q2 2026.
Amylyx Pharmaceuticals was a new Canada Pension Plan Investment Board position in Q2 2026.
Amylyx Pharmaceuticals made up ﹤0.01% of Canada Pension Plan Investment Board's portfolio in Q2 2026, its #1267 holding.
206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Canada Pension Plan Investment Board's 13F filing for Q2 2026, filed 14 Aug 2026.